• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

病毒样颗粒疫苗引发免疫反应,预防针对呼吸道合胞病毒的灭活病毒疫苗增强型疾病。

Virus-like particle vaccine primes immune responses preventing inactivated-virus vaccine-enhanced disease against respiratory syncytial virus.

作者信息

Hwang Hye Suk, Lee Young-Tae, Kim Ki-Hye, Ko Eun-Ju, Lee Youri, Kwon Young-Man, Kang Sang-Moo

机构信息

Center for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA; Department of Microbiology, Chonnam National University Medical School, Gwangju, Republic of Korea.

Center for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA.

出版信息

Virology. 2017 Nov;511:142-151. doi: 10.1016/j.virol.2017.08.022. Epub 2017 Aug 29.

DOI:10.1016/j.virol.2017.08.022
PMID:28846899
Abstract

Formalin inactivated respiratory syncytial virus (FI-RSV) vaccination caused vaccine-enhanced respiratory disease (ERD) upon exposure to RSV in children. Virus-like particles presenting RSV F fusion protein (F VLP) are known to increase T helper type-1 (Th1) immune responses and avoid ERD in animal models. We hypothesized that F VLP would prime immune responses preventing ERD upon subsequent exposure to ERD-prone FI-RSV. Here, we demonstrated that heterologous F VLP priming and FI-RSV boosting of mice prevented FI-RSV vaccine-enhanced lung inflammation and eosinophilia upon RSV challenge. F VLP priming redirected pulmonary T cells toward effector CD8 T cells producing Th1 cytokines and significantly suppressed pulmonary Th2 cytokines. This study suggests that RSV F VLP priming would modulate and shift immune responses to subsequent exposure to ERD-prone FI-RSV vaccine and RSV infection, suppressing Th2 immune-mediated pulmonary histopathology and eosinophilia.

摘要

福尔马林灭活呼吸道合胞病毒(FI-RSV)疫苗接种会导致儿童在接触RSV后出现疫苗增强型呼吸道疾病(ERD)。已知呈现RSV F融合蛋白的病毒样颗粒(F VLP)可增强1型辅助性T细胞(Th1)免疫反应,并在动物模型中避免ERD。我们推测,F VLP会引发免疫反应,在随后接触易引发ERD的FI-RSV时预防ERD。在此,我们证明,对小鼠进行异源F VLP初免并用FI-RSV加强免疫,可在RSV攻击时预防FI-RSV疫苗增强的肺部炎症和嗜酸性粒细胞增多。F VLP初免使肺T细胞转向产生Th1细胞因子的效应性CD8 T细胞,并显著抑制肺部Th2细胞因子。这项研究表明,RSV F VLP初免会调节并改变免疫反应,以应对随后接触易引发ERD的FI-RSV疫苗和RSV感染,抑制Th2免疫介导的肺部组织病理学变化和嗜酸性粒细胞增多。

相似文献

1
Virus-like particle vaccine primes immune responses preventing inactivated-virus vaccine-enhanced disease against respiratory syncytial virus.病毒样颗粒疫苗引发免疫反应,预防针对呼吸道合胞病毒的灭活病毒疫苗增强型疾病。
Virology. 2017 Nov;511:142-151. doi: 10.1016/j.virol.2017.08.022. Epub 2017 Aug 29.
2
Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.含有呼吸道合胞病毒F蛋白的病毒样颗粒疫苗通过调节树突状细胞和效应T细胞的特定亚群提供无肺部疾病的保护。
J Virol. 2015 Nov;89(22):11692-705. doi: 10.1128/JVI.02018-15. Epub 2015 Sep 9.
3
Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.由F糖蛋白的融合后和融合前构象组成的新型呼吸道合胞病毒样颗粒疫苗。
Clin Vaccine Immunol. 2016 Jun 6;23(6):451-9. doi: 10.1128/CVI.00720-15. Print 2016 Jun.
4
Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.含有F蛋白或F蛋白与G蛋白的病毒样颗粒疫苗可使棉鼠免受呼吸道合胞病毒感染,且不会引发肺部炎症。
Hum Vaccin Immunother. 2017 May 4;13(5):1031-1039. doi: 10.1080/21645515.2016.1272743. Epub 2017 Jan 27.
5
Combined virus-like particle and fusion protein-encoding DNA vaccination of cotton rats induces protection against respiratory syncytial virus without causing vaccine-enhanced disease.联合病毒样颗粒和编码融合蛋白的DNA疫苗接种棉鼠可诱导对呼吸道合胞病毒的保护作用,且不会引起疫苗增强性疾病。
Virology. 2016 Jul;494:215-24. doi: 10.1016/j.virol.2016.04.014. Epub 2016 Apr 26.
6
Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.鼻腔内用含单磷酰脂质 A 的病毒体呼吸道合胞病毒疫苗在小鼠和棉鼠中的疗效和安全性。
Vaccine. 2013 Apr 19;31(17):2169-76. doi: 10.1016/j.vaccine.2013.02.043. Epub 2013 Mar 13.
7
CpG in Combination with an Inhibitor of Notch Signaling Suppresses Formalin-Inactivated Respiratory Syncytial Virus-Enhanced Airway Hyperresponsiveness and Inflammation by Inhibiting Th17 Memory Responses and Promoting Tissue-Resident Memory Cells in Lungs.CpG与Notch信号通路抑制剂联合使用,通过抑制Th17记忆反应和促进肺组织驻留记忆细胞,抑制福尔马林灭活的呼吸道合胞病毒增强的气道高反应性和炎症。
J Virol. 2017 Apr 28;91(10). doi: 10.1128/JVI.02111-16. Print 2017 May 15.
8
The number of respiratory syncytial virus (RSV)-specific memory CD8 T cells in the lung is critical for their ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia.肺部呼吸道合胞病毒(RSV)特异性记忆性CD8 T细胞的数量对于它们抑制RSV疫苗增强的肺部嗜酸性粒细胞增多的能力至关重要。
J Immunol. 2008 Dec 1;181(11):7958-68. doi: 10.4049/jimmunol.181.11.7958.
9
Lipopolysaccharide Inhibits FI-RSV Vaccine-enhanced Inflammation Through Regulating Th Responses.脂多糖通过调节 Th 应答抑制 FI-RSV 疫苗增强的炎症反应。
Curr Med Sci. 2019 Jun;39(3):363-370. doi: 10.1007/s11596-019-2044-0. Epub 2019 Jun 17.
10
Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.在棉鼠模型中,低剂量重组融合后或融合前呼吸道合胞病毒F免疫接种引发疫苗增强疾病,与Th1偏向佐剂(GLA-SE)或Th2偏向佐剂(明矾)的存在无关。
J Virol. 2017 Mar 29;91(8). doi: 10.1128/JVI.02180-16. Print 2017 Apr 15.

引用本文的文献

1
Cationic-nanogel nasal vaccine containing the ectodomain of RSV-small hydrophobic protein induces protective immunity in rodents.含有呼吸道合胞病毒小疏水蛋白胞外域的阳离子纳米凝胶鼻用疫苗可在啮齿动物中诱导保护性免疫。
NPJ Vaccines. 2023 Jul 24;8(1):106. doi: 10.1038/s41541-023-00700-3.
2
The Quest for a Respiratory Syncytial Virus Vaccine for Older Adults: Thinking beyond the F Protein.为老年人研发呼吸道合胞病毒疫苗的探索:超越融合蛋白的思考
Vaccines (Basel). 2023 Feb 7;11(2):382. doi: 10.3390/vaccines11020382.
3
Natural killer cells contribute to enhanced respiratory disease after oil-in-water emulsion adjuvanted vaccination against respiratory syncytial virus and infection.
自然杀伤细胞有助于增强水包油乳剂佐剂疫苗接种呼吸道合胞病毒和感染后的呼吸道疾病。
Hum Vaccin Immunother. 2021 Oct 3;17(10):3806-3817. doi: 10.1080/21645515.2021.1915039. Epub 2021 Apr 20.
4
Roles of the Fc Receptor γ-Chain in Inducing Protective Immune Responses after Heterologous Vaccination against Respiratory Syncytial Virus Infection.Fc受体γ链在呼吸道合胞病毒感染异源疫苗接种后诱导保护性免疫反应中的作用
Vaccines (Basel). 2021 Mar 8;9(3):232. doi: 10.3390/vaccines9030232.
5
Natural Killer and CD8 T Cells Contribute to Protection by Formalin Inactivated Respiratory Syncytial Virus Vaccination under a CD4-Deficient Condition.在CD4缺陷条件下,自然杀伤细胞和CD8 T细胞有助于甲醛灭活呼吸道合胞病毒疫苗接种所提供的保护作用。
Immune Netw. 2020 Nov 25;20(6):e51. doi: 10.4110/in.2020.20.e51. eCollection 2020 Dec.
6
Engineering of Live Chimeric Vaccines against Human Metapneumovirus.针对人偏肺病毒的活嵌合疫苗工程
Pathogens. 2020 Feb 19;9(2):135. doi: 10.3390/pathogens9020135.
7
Progress in the development of virus-like particle vaccines against respiratory viruses.抗呼吸道病毒的病毒样颗粒疫苗的研发进展。
Expert Rev Vaccines. 2020 Jan;19(1):11-24. doi: 10.1080/14760584.2020.1711053. Epub 2020 Jan 18.
8
Recombinant live attenuated influenza vaccine viruses carrying CD8 T-cell epitopes of respiratory syncytial virus protect mice against both pathogens without inflammatory disease.携带呼吸道合胞病毒 CD8 T 细胞表位的重组减毒流感疫苗病毒可保护小鼠免受两种病原体感染而不引起炎症性疾病。
Antiviral Res. 2019 Aug;168:9-17. doi: 10.1016/j.antiviral.2019.05.001. Epub 2019 May 7.
9
Respiratory Syncytial Virus Vaccine Approaches: a Current Overview.呼吸道合胞病毒疫苗研究进展:当前概述
Curr Clin Microbiol Rep. 2017 Dec;4:202-207. doi: 10.1007/s40588-017-0074-6. Epub 2017 Oct 16.
10
Immune responses in influenza A virus and human coronavirus infections: an ongoing battle between the virus and host.甲型流感病毒和人类冠状病毒感染中的免疫反应:病毒与宿主之间的持续斗争。
Curr Opin Virol. 2018 Feb;28:43-52. doi: 10.1016/j.coviro.2017.11.002. Epub 2017 Nov 21.